BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9338098)

  • 1. Cyclin dependent kinase inhibitors.
    Harper JW
    Cancer Surv; 1997; 29():91-107. PubMed ID: 9338098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
    Nakayama K; Nakayama K
    Bioessays; 1998 Dec; 20(12):1020-9. PubMed ID: 10048302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
    Rodriguez-Puebla ML; LaCava M; Gimenez-Conti IB; Johnson DG; Conti CJ
    Oncogene; 1998 Oct; 17(17):2251-8. PubMed ID: 9811455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of the cell cycle in cancer.
    Sandhu C; Slingerland J
    Cancer Detect Prev; 2000; 24(2):107-18. PubMed ID: 10917130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).
    Graña X; Reddy EP
    Oncogene; 1995 Jul; 11(2):211-9. PubMed ID: 7624138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H; Wang YC
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver.
    Luedde T; Rodriguez ME; Tacke F; Xiong Y; Brenner DA; Trautwein C
    Hepatology; 2003 Apr; 37(4):833-41. PubMed ID: 12668976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
    Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
    Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
    Pavletich NP
    J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
    Gill RM; Slack R; Kiess M; Hamel PA
    Exp Cell Res; 1998 Oct; 244(1):157-70. PubMed ID: 9770359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-cycle molecules in mesothelioma: an overview.
    Spugnini EP; Campioni M; D'Avino A; Caruso G; Citro G; Baldi A
    J Exp Clin Cancer Res; 2007 Dec; 26(4):443-9. PubMed ID: 18365537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms.
    Suzuki T; Narita T; Uchida-Toita M; Yoshida M
    Virology; 1999 Jul; 259(2):384-91. PubMed ID: 10388662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors.
    Thullberg M; Welcker M; Bartkova J; Kjerulff AA; Lukas J; Högberg J; Bartek J
    Hybridoma; 2000 Feb; 19(1):63-72. PubMed ID: 10768842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular mechanism of cell cycle control].
    Akiyama T
    Nihon Rinsho; 1996 Apr; 54(4):1031-6. PubMed ID: 8920669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKs and CKIs: molecular targets for tissue remodelling.
    Nabel EG
    Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitors in yeast, animals, and plants: a functional comparison.
    De Clercq A; Inzé D
    Crit Rev Biochem Mol Biol; 2006; 41(5):293-313. PubMed ID: 16911957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of CDK regulation.
    Morgan DO
    Nature; 1995 Mar; 374(6518):131-4. PubMed ID: 7877684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.
    Mainprize TG; Taylor MD; Rutka JT; Dirks PB
    J Neurooncol; 2001 Feb; 51(3):205-18. PubMed ID: 11407593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.